Beginning New Clinical Trials, Innovation Recognitions, Expansion in Patent Portfolios, Product Distributions and Offerings -

 Beginning New Clinical Trials, Innovation Recognitions, Expansion in Patent
     Portfolios, Product Distributions and Offerings - Research Report on
               Allscripts, Novavax, Amarin, Acura, and Catalyst

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 27, 2013

NEW YORK, September 27, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting
Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX), Novavax, Inc. (NASDAQ:
NVAX), Amarin Corporation plc (NASDAQ: AMRN), Acura Pharmaceuticals Inc.
(NASDAQ: ACUR), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Allscripts Healthcare Solutions, Inc. Research Report 

On September 6, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts)
announced that Baylor Health Care System (Bayer) has been named a winner of
the 2013 Tech Titans Technology Adopter Award for its outstanding achievement
in the rapid and successful design and implementation of innovations enabled
by Allscripts Open solutions platform. The Company stated that Baylor has
created various custom components for Allscripts Sunrise Clinical Manager and
the enhancements were designed to improve the adoption and use of Computerized
Physician Order Entry (CPOE) and the use of electronic physician
documentation. According to the Company, the Tech Titans award recognizes
companies and individuals who have made outstanding contributions to the
technology industry and to the technology industry in North Texas. "We would
like to congratulate Baylor for this special recognition," said Paul M. Black,
President and CEO of Allscripts. The Full Research Report on Allscripts
Healthcare Solutions, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:


Novavax, Inc. Research Report

On September 24, 2013, Novavax, Inc. (Novavax) announced that after a
successful completion of process improvement studies, it is now finalizing
details on costs and timelines for their next round of clinical studies with
the U.S. Department of Health and Human Services, Biomedical Advanced Research
and Development Authority (BARDA). The Company informed that it preparing to
move forward with these next clinical trials for its quadrivalent seasonal
influenza vaccine candidate and its pandemic influenza vaccine candidate, both
under U.S. INDs. According to Novavax, it plans to start the Quadrivalent
Seasonal Influenza Clinical Trial in Q1 2014 and Pandemic Influenza Clinical
Trial in the U.S. in H1 2014. Stanley C. Erck, President and CEO said,
"Novavax is committed to moving these two vaccine candidates through to
licensure. The clinical trials we have planned for 2014 are important steps in
the completion of that goal." The Full Research Report on Novavax, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:


Amarin Corporation plc Research Report

On September 9, 2013, Amarin Corp. plc (Amarin) announced that its flagship
product, Vascepa® (icosapent ethyl) capsules now has 30 patents issued or
allowed by the United States Patent and Trademark Office (USPTO). Joseph
Zakrzewski, Chairman and CEO of Amarin said, "With 30 patents issued and
allowed and over 30 additional applications pending in the United States,
Amarin now has one of the most extensive, and expanding, patent portfolios
covering a product in the industry, The continued issuance of a variety of
patents covering Vascepa is emblematic of the success achieved at Amarin
toward its goal of protecting the commercial potential of Vascepa to beyond
2030 through patent protection. In addition, Amarin's Vascepa is also
protected by trade secrets and existing manufacturing barriers to entry, along
with anticipated three- or five-year regulatory exclusivity in the United
States." The Full Research Report on Amarin Corporation plc - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


Acura Pharmaceuticals Inc. Research Report

On September 18, 2013, Acura Pharmaceuticals Inc. (Acura Pharmaceuticals)
announced that its next generation pseudoephedrine hydrochloride tablet,
NEXAFED, is now being sold in over 2,600 pharmacies nationwide. The Company
informed that the recent increase in stocks of NEXAFED by Pharmacies can be
attributed to - Meijer Pharmacies who are stocking NEXAFED in all their
pharmacies; the addition of a large regional supermarket chain based in
Florida; and further distribution gains at independent pharmacies. Acura
Pharmaceuticals stated that NEXAFED is readily available to nearly every
pharmacy in the U.S. through national and regional wholesalers. J. Bradley
Rivet, Vice President, Marketing with Acura Pharmaceuticals said, "We're
seeing a significant increase in repeat orders from pharmacies. We've come to
appreciate that once pharmacists begin recommending NEXAFED and are satisfied
with its effectiveness, they typically become an advocate." The Full Research
Report on Acura Pharmaceuticals Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: []


Catalyst Pharmaceutical Partners Inc. Research Report

On September 10, 2013, Catalyst Pharmaceuticals Partners Inc. (Catalyst)
reported the closing of its earlier announced offering of $8.8 million shares
of its common stock in a registered direct public offering. According to the
Company, the offering price was $1.72 per share, with gross proceeds totaling
at c.$15.1 million. Patrick J. McEnany, Catalyst's Chairman and CEO, stated,
"We are pleased to have completed this financing, which we believe, along with
the proceeds from recent warrant exercises, gives us the capital necessary to
fund development of Firdapse™ and allows us to begin new clinical studies for
CPP-115. We are also excited that several high quality fundamental life
science investors, including New Leaf Venture Partners, participated in our
offering." The Full Research Report on Catalyst Pharmaceutical Partners Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA

SOURCE Investors' Reports

Contact: Kristi Saunders, +1-315-982-6420 (North America)
Press spacebar to pause and continue. Press esc to stop.